IFNB1 and myocarditis: In particular, the BICC trial has demonstrated the ability of Beta-interferon to improve myocarditis promoted by entero- and adenovirus [15], while the TIMIC study reported the beneficial influence of immunosuppression on virus-negative inflammatory cardiomyopathy [16,17].